Mushrooms and Cerebral Ischemia: Preclinical Evidence

Mushrooms & Stroke Research

22–44% infarct reduction

A 2025 systematic review confirmed erinacine A from lion's mane reduced stroke-induced brain damage by 22–44% across animal models, the strongest preclinical signal in the mushroom stroke literature.

Spangenberg et al., Frontiers in Pharmacology, 2025

8 compounds

from 6+ mushroom species tested in stroke animal models

0 human trials

no clinical data exists for any of these compounds in stroke

2025 data

Tremella fuciformis hemorrhagic stroke finding with no consumer coverage

Spangenberg et al., Frontiers in Pharmacology, 2025

View as image ↗

In a series of animal experiments conducted over the past 15 years, mushroom-derived compounds reduced stroke-induced brain damage by margins that would be clinically significant if replicated in humans. A 2025 systematic review confirmed that erinacine A from lion's mane reduced the size of dead tissue after blocked blood supply to the brain by 22 to 44 percent across multiple animal models.^[1]

Every one of those experiments was conducted in rats or mice.

The gap between animal model results and human clinical benefit is large and well-documented. No clinical trial has tested any mushroom compound against cerebral ischemia, which is the medical term for a stroke caused by blocked blood flow to the brain. The mushroom compounds cerebral ischemia preclinical evidence reviewed here is promising as a research foundation, but it does not establish that these compounds work in humans. That framing applies to everything that follows.

With that stated: the breadth of this evidence is striking. Eight compounds from six or more mushroom species, acting through at least five distinct mechanisms, have all shown protective effects in standard stroke animal models. This research sits within the broader body of evidence covered in Mushrooms and Cognitive Aging: Can They Protect Your Brain?, and the stroke-specific data is where the animal model evidence is most concentrated and most detailed.

What the Preclinical Evidence Covers, and the Honest Limits It Carries

Before reviewing the compounds, two pieces of context are necessary.

What these animal models test. The most common model used across these studies is called middle cerebral artery occlusion, or MCAO. A thread is passed into the brain's main blood supply artery and blocks it, creating a stroke that mimics what happens when a clot lodges in a human brain. After a set time, the blockage is removed to simulate reperfusion, which is the restoration of blood flow that paradoxically causes a second wave of damage from oxidative stress. Brain tissue that died during the blockage is measured. Behavioral tests assess how well the animal can move, balance, and navigate. This model is the gold standard in stroke research. Its results translate inconsistently to humans.

What the evidence cannot tell us. Animal models of stroke are good at showing that a compound reaches the brain, engages a mechanism, and reduces measurable damage. They are poor at predicting whether an oral supplement provides brain tissue concentrations high enough to do the same thing in a person. Whether these compounds cross the human blood-brain barrier in adequate amounts from an oral dose is unknown for most of them. Whether they interact with standard stroke treatments is untested.

With those limits clearly stated, here is what each compound class has shown.

The eight compound classes with preclinical evidence in stroke models:

1. Erinacine A and C (lion's mane, Hericium erinaceus): 22–44% infarct reduction via Nrf2 antioxidant activation, anti-apoptotic effects, and neurogenesis promotion in MCAO models
2. Cordymin (Cordyceps sinensis): suppression of IL-1β, TNF-α, and C3 inflammatory protein after MCAO-induced focal ischemia in rats
3. Cordyceps sinensis extract: protection of mitochondrial energy production and blockade of the mitochondrial cell death cascade in cerebral ischemic injury
4. Pachymic acid (Poria cocos, Fu Ling): PI3K/Akt-mediated neuroprotection in ischemia/reperfusion injury models
5. Ergostatrien-3β-ol (Antrodia camphorata): dual NF-κB/caspase-3 suppression plus Akt/GSK3/β-catenin neurogenesis activation in ischemic stroke rats
6. Ganoderma lucidum polysaccharides and extracts: hippocampal neuroprotection after ischemia/reperfusion and dual apoptosis/necroptosis prevention in diabetic-stroke models
7. Sparassis crispa beta-glucans: delayed stroke incidence via Akt/eNOS activation in stroke-prone spontaneously hypertensive rats
8. Tremella fuciformis polysaccharides: early brain injury reduction in subarachnoid hemorrhage via P38 MAPK/NF-κB inhibition (2025 data)

Lion's Mane and Erinacines: 22–44% Infarct Reduction in the Standard Stroke Model

The strongest and most current preclinical foundation for mushrooms and stroke protection comes from lion's mane (Hericium erinaceus) and its diterpenoid compounds, a class of small fat-soluble molecules called erinacines.

A 2025 systematic review by Spangenberg and colleagues synthesized the available animal model evidence for erinacines across multiple neurological conditions.^[1] The review confirmed that erinacine A and erinacine C both act through a master regulatory protein called Nrf2. Nrf2 is a molecular switch that, when activated, turns on the cell's own antioxidant defense systems. In ischemia animal models, Nrf2 activation reduced the size of the dead tissue zone by 22 to 44 percent depending on species, dose, and timing of treatment.

The review also confirmed two additional protective effects beyond the antioxidant pathway. Erinacines suppressed the programmed cell death process that occurs when neurons are deprived of oxygen, called apoptosis, at multiple steps in the cascade. They also promoted the growth of new neurons to replace those lost during the stroke, a process called neurogenesis. These are three separate mechanisms operating simultaneously.

A 2024 study by Lee and colleagues tested novel erinacines from lion's mane mycelium in both a mild traumatic brain injury animal model and isolated brain support cells in the lab, finding the same Nrf2-dependent protection against inflammation and neuronal damage.^[12] The TBI and ischemia mechanisms overlap substantially.

Erinacine S, a different compound in the erinacine family, works through an additional pathway. A 2023 study by Lin and colleagues found that erinacine S promotes neuronal regeneration by increasing the production of neurosteroids, which are natural regulatory molecules made inside the brain itself that govern how brain cells grow, connect, and recover from damage.^[13]

The important honest caveat for erinacines specifically: these are small-molecule diterpenoids with demonstrated brain penetration in animal studies. Whether orally consumed erinacines reach neurons in the human brain at protective concentrations has not been established by human pharmacokinetic research. This caveat is explored in detail in Erinacines: The Compounds That Cross the Blood-Brain Barrier and Mushrooms and Blood-Brain Barrier Protection After Stroke.

Cordymin and Cordyceps Sinensis Extract: Two Separate Mechanisms in MCAO Models

Cordyceps mushrooms have produced two distinct compound classes with evidence in stroke animal models: one a purified peptide, the other a crude extract acting on the cell's energy factory.

Cordymin is a peptide, a short protein chain, purified directly from Cordyceps sinensis. A 2012 study by Wang and colleagues tested Cordymin in rats after MCAO-induced focal ischemia, the same blocked-artery model used across most stroke research.^[2] Cordymin reduced three markers of acute brain inflammation: interleukin-1 beta (IL-1β), which triggers the initial inflammatory cascade; tumor necrosis factor alpha (TNF-α), which amplifies it; and a complement protein (C3) involved in the immune response to dead tissue. Neutrophil infiltration into brain tissue, another marker of damaging inflammation, also decreased. Neurobehavioral function scores improved.

A 2020 study by Bai and colleagues took a different approach, testing a Cordyceps sinensis whole extract rather than a purified compound.^[3] The mechanism was also different: the extract protected the mitochondria, the organelles inside neurons that generate the energy cells need to survive, from the chain of events that causes them to trigger cell death during ischemia. When a neuron loses blood supply, its mitochondria fail, and that failure launches the apoptotic cascade. Cordyceps extract preserved mitochondrial function and blocked that launch sequence.

A 2024 comprehensive review by Li and colleagues synthesized the full mechanistic picture of Cordyceps against cerebrovascular ischemic injury across multiple studies.^[4] The review identified five protective pathways: improving blood flow through the ischemic region, neutralizing the reactive oxygen molecules that accumulate when blood flow is restored, suppressing the inflammatory cascade in brain tissue, blocking cell death at multiple steps in the apoptotic pathway, and promoting regeneration of damaged tissue. No single Cordyceps compound activates all five simultaneously; the evidence spans a range of compounds and preparations.

Triterpenoids From Poria and Antrodia: Blocking Cell Death and Activating Regeneration

Two separate mushroom species have produced triterpenoid compounds, a class of fat-soluble bioactive molecules, with complementary mechanisms in ischemic stroke models.

Pachymic acid comes from Poria cocos, a fungus also known as Fu Ling in traditional Chinese medicine. A 2020 study by Pang and colleagues tested it in rats after ischemia/reperfusion injury, the model that simulates the second wave of damage when blood flow is restored after a stroke.^[5] Pachymic acid activated the PI3K/Akt signaling chain, a cell survival pathway that tells neurons to stay alive rather than undergo programmed death. Brain infarct size decreased. Neurological deficit scores improved. The mechanism was specific enough that the researchers could block the protective effect by inhibiting the PI3K portion of the pathway, confirming this was the working mechanism and not a general effect.

The second triterpenoid comes from Antrodia camphorata, the same rare Taiwanese mushroom discussed in the fermentation biotechnology literature for its submerged culture production. A 2019 study by Wang and colleagues tested ergostatrien-3β-ol, a sterol compound found in Antrodia, in ischemic stroke rats.^[6] This compound acted on two separate pathways simultaneously. First, it suppressed NF-κB, the molecular switch that activates the inflammatory response, and downstream caspase-3 activity, which is the direct executioner molecule in neuronal cell death. Second, it activated the Akt/GSK3/β-catenin pathway, which is the signaling chain that drives new neuron growth from neural stem cells. The compound was both protecting existing neurons from death and promoting replacement of neurons that had already died.

The combination of anti-cell death and pro-neurogenesis in a single compound is unusual in stroke research, and this particular mechanism has not appeared in any consumer health content.

Ganoderma Lucidum: Seven Days of Pretreatment and a Unique Diabetic Stroke Finding

Reishi (Ganoderma lucidum) has produced preclinical evidence in two separate stroke models that cover different neurological contexts.

A 2014 study by Zhang and colleagues tested the effect of 7 consecutive days of Ganoderma lucidum pretreatment before inducing ischemia/reperfusion injury in rats.^[7] The pretreatment approach tests whether the compound protects neurons before damage occurs, which is relevant to prevention rather than acute treatment. The results showed reduced neuronal loss in the hippocampus, the brain region most vulnerable to ischemic damage and most important for memory. Levels of malondialdehyde (a marker of oxidative damage from cell membranes being destroyed) decreased. The inflammatory cytokines TNF-α and IL-8 also decreased. At the same time, superoxide dismutase activity (the brain's own antioxidant enzyme) increased. Learning and memory performance on behavioral tests improved after the ischemic event.

The second Ganoderma study targets a population angle that no consumer content has addressed. A 2015 study by Xuan and colleagues used a type 2 diabetic mouse model specifically, because type 2 diabetes is one of the strongest risk factors for stroke and strokes in diabetic brains cause more extensive damage than in non-diabetic brains.^[8] A water-soluble extract from Ganoderma lucidum mycelia protected the diabetic mouse brain from hypoxia/ischemia injury through a notable mechanism: it prevented both apoptosis (the controlled form of programmed cell death that depleted neurons undergo) and necroptosis (a more explosive form of cell death that releases toxic inflammatory contents into surrounding tissue). Most stroke compounds in the research literature target one cell death pathway or the other. The Ganoderma extract blocked both.

Three Species With No Consumer Coverage: Sparassis crispa, Antrodia Embolic Data, and 2025 Tremella Hemorrhagic Evidence

Three mushroom species with preclinical stroke data have received essentially no attention in consumer health content. Each offers a distinct angle not covered elsewhere in the mushroom stroke literature.

Sparassis crispa. This cauliflower-shaped edible mushroom, rich in beta-glucans and found in East Asian cuisine, was tested in stroke-prone spontaneously hypertensive rats (SHRSP), a genetic rat model that develops strokes naturally without laboratory induction. A 2011 study by Yoshitomi and colleagues found that Sparassis crispa administration delayed both stroke onset and death in these rats, while also decreasing blood pressure and increasing blood flow in the cerebral cortex.^[10] The mechanism ran through the Akt/eNOS pathway. eNOS is an enzyme that produces nitric oxide, a molecule that keeps blood vessels relaxed and blood flowing. When eNOS activity in the brain is too low, vessels constrict, contributing to both high blood pressure and the risk of vessel occlusion. Sparassis crispa increased eNOS phosphorylation (activation) in the cerebral cortex, which kept vessels more dilated. This is a vascular protection mechanism rather than a direct neuroprotective one; the compound may work partly by reducing the conditions that cause strokes, not just the damage once a stroke occurs.

Antrodia camphorata embolic stroke. The same Taiwanese mushroom discussed in the triterpenoid section above was tested in a different model with a different focus. A 2014 study by Lee and colleagues tested Antrodia camphorata extract specifically in an embolic stroke model, designed to mimic clot-based stroke as opposed to surgical artery occlusion, and measured hemorrhagic transformation risk.^[9] Hemorrhagic transformation is a dangerous complication where a clot-based stroke converts into a bleeding stroke after treatment. Standard thrombolytic drugs (clot-busters) carry this risk. The Antrodia extract reduced brain damage from the embolic stroke without increasing hemorrhagic transformation risk. In a research context where many neuroprotective compounds fail because they make bleeding worse, that safety profile is relevant.

Tremella fuciformis. Snow fungus is best known for its use in traditional Asian cuisine and skin care formulations. Its stroke-relevant research is more recent and has received no consumer coverage. A 2025 study by Wan and colleagues tested Tremella fuciformis polysaccharides in a subarachnoid hemorrhage model.^[11] Subarachnoid hemorrhage is a specific type of hemorrhagic stroke where blood leaks into the space surrounding the brain rather than into brain tissue itself. It accounts for about 5% of strokes but has disproportionately high mortality and disability rates. The Tremella polysaccharides reduced early brain injury after subarachnoid hemorrhage by inhibiting the KDR-mediated P38 MAPK/NF-κB inflammatory cascade, a chain of molecular events that amplifies the initial brain injury in the hours after the bleed. An important note: this is hemorrhagic stroke data, not ischemic stroke data. The mechanism and clinical context are different from the other compounds reviewed here.

For a comprehensive view of how these compounds may support brain health more broadly, see Mushrooms and Stroke Recovery: Neuroprotective Research, Can Mushrooms Help After a Stroke? Anti-Inflammatory Brain Effects, and Best Mushrooms for Brain Health in Older Adults. The neuroplasticity side of stroke recovery is examined in Mushrooms and Post-Stroke Neuroplasticity: Can Fungi Accelerate Brain Rewiring?

For readers interested in TBI research using similar compounds, the mechanistic overlap with stroke is significant: Mushrooms for Traumatic Brain Injury: Neuroprotective Research covers how erinacines and cordyceps have been studied across both types of acquired brain injury.

The Bottom Line

Eight mushroom-derived compounds across at least six species have shown neuroprotective effects in cerebral ischemia animal models. The evidence spans multiple compound classes (diterpenoids, peptides, polysaccharides, triterpenoids, sterols) and multiple mechanisms (Nrf2 antioxidant activation, PI3K/Akt cell survival signaling, NF-κB inflammatory suppression, mitochondrial protection, eNOS vascular support). The strongest individual evidence is for erinacine A, supported by a 2025 systematic review showing 22–44% infarct reduction in MCAO models. No human clinical trials have tested any of these compounds in stroke patients. The preclinical evidence establishes a mechanistic foundation but cannot be used to draw conclusions about human efficacy.

Frequently Asked Questions

What is cerebral ischemia?

Cerebral ischemia is the medical term for a stroke caused by blocked blood flow to a region of the brain. When blood supply is cut off, neurons begin to die from oxygen and glucose deprivation within minutes. Most strokes are ischemic, caused by a clot or narrowed vessel. The blocked-artery laboratory model used in most mushroom stroke research, middle cerebral artery occlusion (MCAO), mimics this by inserting a thread to block the brain's main blood supply artery, creating a measurable zone of dead tissue used to evaluate compound effectiveness.

Which mushroom compounds protect against stroke?

Eight mushroom-derived compounds have shown protective effects in cerebral ischemia animal models: erinacine A and C from lion's mane (22–44% infarct reduction); cordymin peptide from Cordyceps sinensis (IL-1β and TNF-α suppression after MCAO); Cordyceps sinensis extract (mitochondrial protection); pachymic acid from Poria cocos (PI3K/Akt cell survival activation); ergostatrien-3β-ol from Antrodia camphorata (anti-inflammatory plus neurogenesis); Ganoderma lucidum polysaccharides (hippocampal neuroprotection and dual cell death pathway blockade); Sparassis crispa beta-glucans (eNOS-mediated vascular protection); and Tremella fuciformis polysaccharides (subarachnoid hemorrhage protection). All evidence comes from animal models; no human clinical trials exist.

What does erinacine A do to the brain during ischemia?

Erinacine A from lion's mane (Hericium erinaceus) reduces ischemia-induced brain damage through three mechanisms working in parallel: it activates Nrf2, a regulatory protein that switches on the cell's antioxidant defense systems; it suppresses apoptosis, the programmed cell death process triggered in oxygen-deprived neurons; and it promotes neurogenesis, the growth of new neurons to replace those lost. A 2025 systematic review of animal model data confirmed 22–44% reductions in dead brain tissue from erinacine A treatment across multiple MCAO experiments. No human data exists for erinacine A in stroke.

Does cordyceps protect the brain from stroke?

In preclinical animal models, two Cordyceps compounds have shown brain protection in stroke scenarios through different mechanisms. Cordymin, a peptide from Cordyceps sinensis, reduced IL-1β, TNF-α, and C3 inflammatory proteins and improved neurobehavioral scores after MCAO-induced ischemia in rats. A Cordyceps sinensis whole extract protected mitochondrial function in cerebral ischemic injury, blocking the energy failure that triggers neuronal death. A 2024 comprehensive review identified five separate mechanisms by which Cordyceps compounds act against cerebrovascular ischemic injury. All evidence is from animal studies; no clinical trials have tested cordyceps in human stroke.

Which mushrooms have the strongest preclinical evidence for stroke?

By quality and quantity of evidence, lion's mane (Hericium erinaceus) has the strongest foundation, supported by a 2025 systematic review confirming erinacine A's 22–44% infarct reduction with well-characterized Nrf2 and anti-apoptotic mechanisms. Cordyceps sinensis has evidence from both a purified peptide (cordymin) and a whole extract, supported by a 2024 comprehensive review of five separate mechanisms. Ganoderma lucidum (reishi) has two separate animal studies covering hippocampal protection and a unique diabetic-stroke model. Poria cocos and Antrodia camphorata both have triterpenoid-specific animal data with clearly characterized signaling pathways. All species remain at the preclinical stage for stroke specifically.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2. Source details for this reference are not yet available.
3. 3. Source details for this reference are not yet available.
4. 4. Source details for this reference are not yet available.
5. 5. Source details for this reference are not yet available.
6. 6. Source details for this reference are not yet available.
7. 7. Source details for this reference are not yet available.
8. 8. Source details for this reference are not yet available.
9. 9. Source details for this reference are not yet available.
10. 10. Source details for this reference are not yet available.
11. 11. Source details for this reference are not yet available.
12. 12. Source details for this reference are not yet available.
13. 13. Source details for this reference are not yet available.